nach oben

World Journal of Urology

Erschienen in:

20.02.2019 | Topic Paper

The role of MRI for detection and staging of radio- and focal therapy-recurrent prostate cancer

verfasst von: Henk van der Poel, Nikos Grivas, Pim van Leeuwen, Stijn Heijmink, Ivo Schoots

Erschienen in: World Journal of Urology | Ausgabe 8/2019

Einloggen, um Zugang zu erhalten

Abstract

Local recurrent prostate cancer after radical treatment is found in the majority of men with a rising PSA. Salvage treatment procedures for recurrent disease, such as radiation therapy and ablative procedures, can provide long-term responses in well-selected cases. Prostate magnetic resonance imaging (MRI) allows diagnosis and staging, and the value provides information on treatment selection, treatment planning and treatment guidance in local recurrent prostate cancer.

Zumsteg ZS et al (2015) Anatomical patterns of recurrence following biochemical relapse in the dose escalation era of external beam radiotherapy for prostate cancer. J Urol 194:1624–1630PubMedPubMedCentral

Breeuwsma AJ et al (2010) Detection of local, regional, and distant recurrence in patients with psa relapse after external-beam radiotherapy using (11)C-choline positron emission tomography. Int J Radiat Oncol Biol Phys 77:160–164PubMed

Philippou Y, Parker RA, Volanis D, Gnanapragasam VJ (2016) Comparative oncologic and toxicity outcomes of salvage radical prostatectomy versus nonsurgical therapies for radiorecurrent prostate cancer: a meta-regression analysis. Eur Urol Focus 2:158–171PubMed

van der Poel HG et al (2018) Focal therapy in primary localised prostate cancer: the European association of urology position in 2018. Eur Urol 74:84–91PubMed

Calais J et al (2018) Potential impact of (68)Ga-PSMA-11 PET/CT on prostate cancer definitive radiation therapy planning. J Nucl Med. https://doi.org/10.2967/jnumed.118.209387(pii: jnumed.118.209387) PubMedPubMedCentral

Iravani A et al (2017) (68)Ga PSMA-11 PET with CT urography protocol in the initial staging and biochemical relapse of prostate cancer. Cancer Imaging 17:31PubMedPubMedCentral

Sathianathen NJ, Butaney M, Konety BR (2018) The utility of PET-based imaging for prostate cancer biochemical recurrence: a systematic review and meta-analysis. World J Urol. https://doi.org/10.1007/s00345-018-2403-7 PubMed

Koerber SA et al (2018) (68)Ga-PSMA-11 PET/CT in primary and recurrent prostate carcinoma: implications for radiotherapeutic management in 121 patients. J Nucl Med (pii: jnumed.118.211086)

Herlemann A et al (2017) Salvage lymph node dissection after (68)Ga-PSMA or (18)F-FEC PET/CT for nodal recurrence in prostate cancer patients. Oncotarget 8:84180–84192PubMedPubMedCentral

10.

von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G (2016) (68)Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/computed tomography for prostate cancer: a systematic review and meta-analysis. Eur Urol Focus. https://doi.org/10.1016/j.euf (pii: S2405-4569(16)30160-2).

11.

Caroli P et al (2018) (68)Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients. Eur J Nucl Med Mol Imaging. https://doi.org/10.1007/s00259-018-4067-3 PubMed

12.

Perera M et al (2016) Sensitivity, specificity, and predictors of positive (68)Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol 70:926–937PubMed

13.

Maurer T, Eiber M, Schwaiger M, Gschwend JE (2016) Current use of PSMA-PET in prostate cancer management. Nature Rev Urol 13:226–235

14.

Eissa A et al (2018) The role of 68Ga-PSMA PET/CT scan in biochemical recurrence after primary treatment for prostate cancer: a systematic review of literature. Miner Urol Nefrol. https://doi.org/10.23736/S0393-2249.18.03081-3

15.

Perera M et al (2016) Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol 70:926–937PubMed

16.

Giesel FL et al (2016) Intra-individual comparison of (68)Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer. Eur J Nucl Med Mol Imaging 43:1400–1406

17.

Zamboglou C et al (2017) Comparison of (68)Ga-HBED-CC PSMA-PET/CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology. Theranostics 7:228–237PubMedPubMedCentral

18.

Zattoni F et al (2017) Detection of recurrent prostate cancer after primary radiation therapy: an evaluation of the role of multiparametric 3T magnetic resonance imaging with endorectal coil. Pract Radiat Oncol 7:42–49PubMed

19.

Sala E et al (2006) Endorectal MR imaging before salvage prostatectomy: tumor localization and staging. Radiology 238:176–183PubMed

20.

Akin O et al (2011) Incremental value of diffusion weighted and dynamic contrast enhanced MRI in the detection of locally recurrent prostate cancer after radiation treatment: preliminary results. Eur Radiol 21:1970–1978PubMedPubMedCentral

21.

de Rooij M, Hamoen EH, Witjes JA, Barentsz JO, Rovers MM (2016) Accuracy of magnetic resonance imaging for local staging of prostate cancer: a diagnostic meta-analysis. Eur Urol 70:233–245PubMed

22.

Weinreb JC et al (2016) PI-RADS prostate imaging—reporting and data system: 2015, version 2. Eur Urol 69:16–40PubMed

23.

Grivas N et al (2018) Seminal vesicle invasion on multi-parametric magnetic resonance imaging: correlation with histopathology. Eur J Radiol 98:107–112PubMed

24.

Maurer T, Eiber M, Fanti S, Budaus L, Panebianco V (2016) Imaging for prostate cancer recurrence. Eur Urol Focus 2:139–150PubMed

25.

Vargas HA, Wassberg C, Akin O, Hricak H (2012) MR imaging of treated prostate cancer. Radiology 262:26–42PubMed

26.

Schiavina R et al (2013) The dilemma of localizing disease relapse after radical treatment for prostate cancer: which is the value of the actual imaging techniques? Curr Radiopharmaceuticals 6:92–95

27.

Rouviere O, Vitry T, Lyonnet D (2010) Imaging of prostate cancer local recurrences: why and how? Eur Radiol 20:1254–1266PubMed

28.

Luzurier A et al (2018) Dynamic contrast-enhanced imaging in localizing local recurrence of prostate cancer after radiotherapy: limited added value for readers of varying level of experience. J Magn Reson Imaging 48(4):1012–1023PubMed

29.

Donati OF et al (2013) Multiparametric prostate MR imaging with T2-weighted, diffusion-weighted, and dynamic contrast-enhanced sequences: are all pulse sequences necessary to detect locally recurrent prostate cancer after radiation therapy? Radiology 268:440–450PubMed

30.

Lotte R et al (2018) Multiparametric MRI for suspected recurrent prostate cancer after HIFU: is DCE still needed? Eur Radiol 28(9):3760–3769PubMed

31.

Martino P et al (2011) Role of imaging and biopsy to assess local recurrence after definitive treatment for prostate carcinoma (surgery, radiotherapy, cryotherapy, HIFU). World J Urol 29:595–605PubMed

32.

Rouviere O et al (2010) Prostate cancer transrectal HIFU ablation: detection of local recurrences using T2-weighted and dynamic contrast-enhanced MRI. Eur Radiol 20:48–55PubMed

33.

Rosset R et al (2017) Can pre- and postoperative magnetic resonance imaging predict recurrence-free survival after whole-gland high-intensity focused ablation for prostate cancer? Eur Radiol 27:1768–1775PubMed

34.

Panebianco V et al (2014) Metabolic atrophy and 3-T 1H-magnetic resonance spectroscopy correlation after radiation therapy for prostate cancer. BJU Int 114:852–859PubMed

35.

Moman MR, van der Poel HG, Battermann JJ, Moerland MA, van Vulpen M (2010) Treatment outcome and toxicity after salvage 125-I implantation for prostate cancer recurrences after primary 125-I implantation and external beam radiotherapy. Brachytherapy 9:119–125PubMed

36.

van den Bos W et al (2015) Salvage ablative therapy in prostate cancer: international multidisciplinary consensus on trial design. Urol Oncol 33(495):e491–497

37.

Menard C et al (2015) MR-guided prostate biopsy for planning of focal salvage after radiation therapy. Radiology 274:181–191PubMed

38.

Kanthabalan A et al (2015) The FORECAST study—focal recurrent assessment and salvage treatment for radiorecurrent prostate cancer. Contemporary Clin trials 44:175–186

39.

Golbari NM, Katz AE (2017) Salvage therapy options for local prostate cancer recurrence after primary radiotherapy: a literature review. Curr Urol Rep 18:63PubMed

40.

Miszczyk L, Stapor-Fudzinska M, Miszczyk M, Maciejewski B, Tukiendorf A (2018) Salvage cyberknife-based reirradiation of patients with recurrent prostate cancer: the single-center experience. Technol Cancer Res Treat 17:1533033818785496PubMedPubMedCentral

41.

Mbeutcha A et al (2017) Salvage prostate re-irradiation using high-dose-rate brachytherapy or focal stereotactic body radiotherapy for local recurrence after definitive radiation therapy. Radiat Oncol 12:49PubMedPubMedCentral

42.

Duijzentkunst DA, Peters M, van der Voort van Zyp JR, Moerland MA, van Vulpen M (2016) Focal salvage therapy for local prostate cancer recurrences after primary radiotherapy: a comprehensive review. World J Urol 34:1521–1531PubMedPubMedCentral

43.

Peters M et al (2013) Patterns of outcome and toxicity after salvage prostatectomy, salvage cryosurgery and salvage brachytherapy for prostate cancer recurrences after radiation therapy: a multi-center experience and literature review. World J Urol 31:403–409PubMed

44.

Chade DC et al (2011) Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. Eur Urol 60:205–210PubMedPubMedCentral

45.

Peters M et al (2014) Focal salvage iodine-125 brachytherapy for prostate cancer recurrences after primary radiotherapy: a retrospective study regarding toxicity, biochemical outcome and quality of life. Radiother Oncol 112:77–82PubMed

46.

Hsu CC et al (2013) Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer. Int J Radiat Oncol Biol Phys 85:370–377PubMed

47.

Maenhout M et al (2017) Second salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer. J Contemp Brachytherapy 9:161–166PubMedPubMedCentral

48.

Li YH et al (2015) Salvage focal prostate cryoablation for locally recurrent prostate cancer after radiotherapy: initial results from the cryo on-line data registry. Prostate 75:1–7PubMed

49.

Mouraviev V, Spiess PE, Jones JS (2012) Salvage cryoablation for locally recurrent prostate cancer following primary radiotherapy. Eur Urol 61:1204–1211PubMed

50.

Valerio M et al (2017) Magnetic resonance imaging-transrectal ultrasound fusion focal cryotherapy of the prostate: a prospective development study. Urol Oncol 35:150 e151–150 e157PubMed

51.

Overduin CG, Jenniskens SFM, Sedelaar JPM, Bomers JGR, Futterer JJ (2017) Percutaneous MR-guided focal cryoablation for recurrent prostate cancer following radiation therapy: retrospective analysis of iceball margins and outcomes. Eur Radiol 27:4828–4836PubMedPubMedCentral

52.

Rouviere O, Sbihi L, Gelet A, Chapelon JY (2013) Salvage high-intensity focused ultrasound ablation for prostate cancer local recurrence after external-beam radiation therapy: prognostic value of prostate MRI. Clin Radiol 68:661–667PubMed

53.

Coakley FV et al (2004) Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience. Radiology 233:441–448PubMed

54.

Panebianco V et al (2010) Role of magnetic resonance spectroscopic imaging ([(1)H]MRSI) and dynamic contrast-enhanced MRI (DCE-MRI) in identifying prostate cancer foci in patients with negative biopsy and high levels of prostate-specific antigen (PSA). Radiol Med (Torino) 115:1314–1329

55.

Alonzo F et al (2016) Detection of locally radio-recurrent prostate cancer at multiparametric MRI: Can dynamic contrast-enhanced imaging be omitted? Diagn Interventional Imaging 97:433–441

Titel: The role of MRI for detection and staging of radio- and focal therapy-recurrent prostate cancer
verfasst von: Henk van der Poel
Nikos Grivas
Pim van Leeuwen
Stijn Heijmink
Ivo Schoots
Publikationsdatum: 20.02.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: World Journal of Urology / Ausgabe 8/2019
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-019-02677-y

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2019

Oncologic outcomes after robot-assisted versus open radical cystectomy: a systematic review and meta-analysis

Mitochondrial PIWI-interacting RNAs are novel biomarkers for clear cell renal cell carcinoma

Is it worth to perform salvage radical prostatectomy for radio-recurrent prostate cancer? A literature review

68Ga-PSMA PET/CT-based metastasis-directed radiotherapy for oligometastatic prostate cancer recurrence after radical prostatectomy